DOCSLIB.ORG

Official Journal L 135

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ISSN 0378-6978 Official Journal L 135 Volume 42 of the European Communities 29 May 1999 English edition Legislation Contents I Acts whose publication is obligatory = Council Regulation (EC) No 1110/1999 of 10 May 1999 providing for duty- free treatment of specified pharmaceutical active ingredients bearing an international non-proprietary name (INN) from the World Health Organi- sation and specified products used for the manufacture of finished pharma- ceutical products ............................................................. 1 Commission Regulation (EC) No 1111/1999 of 28 May 1999 establishing the standard import values for determining the entry price of certain fruit and vegetables 16 Commission Regulation (EC) No 1112/1999 of 28 May 1999 setting the amounts of aid for the supply of rice products from the Community to the Canary Islands ...... 18 Commission Regulation (EC) No 1113/1999 of 28 May 1999 setting the amounts of aid for the supply of rice products from the Community to the Azores and Madeira 20 Commission Regulation (EC) No 1114/1999 of 28 May 1999 amending Regulation (EEC) No 1833/92 setting the amounts of aid for the supply of cereals products from the Community to the Azores and Madeira ....................................... 22 Commission Regulation (EC) No 1115/1999 of 28 May 1999 amending Regulation (EEC) No 1832/92 setting the amounts of aid for the supply of cereals products from the Community to the Canary Islands ........................................... 24 Commission Regulation (EC) No 1116/1999 of 28 May 1999 amending Regulation (EEC) No 391/92 setting the amounts of aid for the supply of cereals products from the Community to the French overseas departments .............................. 26 Commission Regulation (EC) No 1117/1999 of 28 May 1999 fixing the maximum export refund on wholly milled long grain rice in connection with the invitation to tender issued in Regulation (EC) No 2566/98 ..................................... 28 Price: EUR 19,50 (Continued overleaf) Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally EN valid for a limited period. The titles of all other acts are printed in bold type and preceded by an asterisk. Contents (continued) Commission Regulation (EC) No 1118/1999 of 28 May 1999 fixing the maximum subsidy for the export of husked long grain rice to the island of Réunion referred to in Regulation (EC) No 2563/98 . ................................................ 29 Commission Regulation (EC) No 1119/1999 of 28 May 1999 fixing the maximum export refund on wholly milled medium round grain and long grain A rice in connection with the invitation to tender issued in Regulation (EC) No 2565/98 ...... 30 Commission Regulation (EC) No 1120/1999 of 28 May 1999 fixing the maximum export refund on wholly milled round grain, medium grain and long grain A rice in connection with the invitation to tender issued in Regulation (EC) No 2564/98 ...... 31 Commission Regulation (EC) No 1121/1999 of 28 May 1999 fixing the maximum export refund on wholly milled round grain rice in connection with the invitation to tender issued in Regulation (EC) No 770/1999 .................................... 32 = Commission Regulation (EC) No 1122/1999 of 28 May 1999 rectifying Regu- lation (EC) No 883/1999 on the issue of system B export licences in the fruit and vegetables sector ......................................................... 33 = Commission Regulation (EC) No 1123/1999 of 28 May 1999 on a sale by tender of beef held by certain intervention agencies for export ............... 34 = Commission Regulation (EC) No 1124/1999 of 28 May 1999 amending Regu- lations (EC) No 1524/98, (EEC) No 2999/92 and (EC) No 3010/94 and fixing the aid for the supply of processed fruit and vegetables to the French over- seas departments, Madeira and the Canary Islands ........................... 39 = Commission Regulation (EC) No 1125/1999 of 28 May 1999 amending Regu- lation (EC) No 111/1999 laying down general rules for the application of Council Regulation (EC) No 2802/98 on a programme to supply agricultural products to the Russian Federation ........................................... 41 = Commission Regulation (EC) No 1126/1999 of 28 May 1999 fixing, for the purposes of Regulation (EC) No 411/97, the ceiling for Community financial assistance granted to producer organisations setting up operational funds for 1998 ....................................................................... 47 = Commission Regulation (EC) No 1127/1999 of 28 May 1999 amending Regu- lation (EEC) No 3719/88 laying down common detailed rules for the applica- tion of the system of import and export licences and advance fixing certi- ficates for agricultural products .............................................. 48 = Commission Regulation (EC) No 1128/1999 of 28 May 1999 laying down detailed rules of application for a tariff quota for calves weighing not more than 80 kilograms originating in certain third countries ..................... 50 = Commission Regulation (EC) No 1129/1999 of 28 May 1999 fixing for the 1999/2000 marketing year the production aid for tinned pineapple and the minimum price to be paid to pineapple producers ........................... 57 = Commission Regulation (EC) No 1130/1999 of 28 May 1999 reducing, for the 1999/2000 marketing year, the amount of aid for lemons delivered for processing following an overrun of the processing threshold ................. 59 EN (Continued on inside back cover) Contents (continued) Commission Regulation (EC) No 1131/1999 of 28 May 1999 fixing the refunds applicable to cereal and rice sector products supplied as Community and national food aid ........................................................................ 60 Commission Regulation (EC) No 1132/1999 of 28 May 1999 altering the export refunds on rice and broken rice . ................................................ 62 Commission Regulation (EC) No 1133/1999 of 28 May 1999 on the supply of beef to Russia ......................................................................... 64 Commission Regulation (EC) No 1134/1999 of 28 May 1999 on the supply to Russia of common wheat and rye of bread-making quality ................................ 75 Commission Regulation (EC) No 1135/1999 of 28 May 1999 opening a second invitation to tender for the mobilisation of pigmeat on the Community market with a view to its subsequent delivery to Russia. ........................................ 85 COURT OF JUSTICE Court of First Instance of the European Communities = Amendments to the rules of procedure of the Court of First Instance of the European Communities to enable it to give decisions in cases when consti- tuted by a single judge of 17 May 1999 ........................................ 92 II Acts whose publication is not obligatory Commission 1999/353/ECSC: = Commission Decision of 28 May 1999 terminating the anti-dumping proceeding concerning imports into the Community of certain stainless steel heavy plates originating in Slovenia and South Africa (notified under document number C(1999) 1383) ................................................ 95 EN 29. 5. 1999 EN Official Journal of the European Communities L 135/1 I (Acts whose publication is obligatory) COUNCIL REGULATION (EC) No 1110/1999 of 10 May 1999 providing for duty-free treatment of specified pharmaceutical active ingredients bearing an international non-proprietary name (INN) from the World Health Organisation and specified products used for the manufacture of finished phar- maceutical products THE COUNCIL OF THE EUROPEAN UNION, (5) Whereas the second such review has taken place with the conclusion that additional INNs and products used for production and manufacture of finished pharmaceutical products should be Having regard to the Treaty establishing the European granted duty-free treatment and that the list of Community, and in particular Article 113 thereof, specified prefixes and suffixes for salts and esters of INNs should be expanded, Having regard to the proposal from the Commission, (1) Whereas, in the course of the Uruguay Round HAS ADOPTED THIS REGULATION: negotiations, the Community and a number of countries discussed duty-free treatment of pharma- ceutical products; Article 1 As from 1 July 1999 the Community shall accord duty- Whereas the participants in those discussions (2) free treatment for the INNs listed in Annex I as well as concluded that, in addition to products falling the salts, esters and hydrates of such products. within the Harmonised System (HS) Chapter 30 and HS Headings 2936, 2937, 2939 and 2941, duty- free treatment should be given to designated phar- maceutical active ingredients bearing an inter- Article 2 national non-proprietary name (INN) from the World Health Organisation, as well as specified salts, esters and hydrates of such products, and also As from 1 July 1999 the Community shall accord duty- to designated products used for the production and free treatment for the products used in the production manufacture of finished pharmaceutical products; and manufacture of finished pharmaceutical products listed in Annex II. (3) Whereas the results of the discussions, as set out in the Record of Discussions, were incorporated into Article 3 the tariff schedules of the participants annexed to the Marrakesh Protocol to GATT 1994; As from 1 July 1999 the specified prefixes and suffixes of INNs eligible for duty-free treatment shall include those listed in Annex III.
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project

    HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project

    University of Rhode Island DigitalCommons@URI Infectious Diseases in Corrections Report (IDCR) 2003 HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project Follow this and additional works at: http://digitalcommons.uri.edu/idcr Recommended Citation HIV & Hepatitis Education Prison Project, "HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6" (2003). Infectious Diseases in Corrections Report (IDCR). Paper 46. http://digitalcommons.uri.edu/idcr/46 This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. HIV & HEPATITIS EDUCATION PRISON HEPJune 2003 Vol. 6, Issue 6 P REPORT PROJECT Infectious Diseases in Corrections SPONSOREDBYTHEBROWNMEDICALSCHOOLOFFICEOFCONTINUINGMEDICALEDUCATION. ABOUT HEPP Long-Term Toxicities Associated with HIV and HEPP Report, a forum for Antiretroviral Therapy correctional problem solving, targets correctional physicians, nurses, By Peter J. Piliero, M.D.*, Associate Professor of Medicine, Albany Medical College administrators, outreach workers, and Soon after the introduction of the first antiretroviraldine (3TC) have also been associated with pan- case managers. Published monthly (ARV) agent, zidovudine (AZT), drug-related toxi-creatitis. There may be an added potential for pan- and distributed by email and fax, cities became recognized and well-characterized.creatitis when using combinations of these nucle- HEPP Report provides up-to-the Things have since become more complicated;oside reverse transcriptase inhibitors (NRTIs). moment information HIV/AIDS, there are now 17 ARV agents in four distinct class-Importantly, the concomitant use of alcohol hepatitis, and other infectious es.
  • Coumarin-Piperazine Derivatives As Biologically Active Compounds

    Coumarin-Piperazine Derivatives As Biologically Active Compounds

    Saudi Pharmaceutical Journal 28 (2020) 220–232 Contents lists available at ScienceDirect Saudi Pharmaceutical Journal journal homepage: www.sciencedirect.com Review Coumarin-piperazine derivatives as biologically active compounds Kinga Ostrowska Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02 097 Warsaw, Poland article info abstract Article history: A number of psychiatric disorders, including anxiety, schizophrenia, Parkinson’s disease, depression and Received 3 May 2019 others CNS diseases are known to induce defects in the function of neural pathways sustained by the neu- Accepted 29 November 2019 rotransmitters, like dopamine and serotonin. N-arylpiperazine moiety is important for CNS-activity, par- Available online 7 December 2019 ticularly for serotonergic and dopaminergic activity. In the scientific literature there are many examples of coumarin-piperazine derivatives, particularly with arylpiperazines linked to a coumarin system via an Keywords: alkyl liner, which can modulate serotonin, dopamine and adrenergic receptors. Numerous studies have Coumarin revealed that the inclusion of a piperazine moiety could occasionally provide unexpected improvements Arylpiperazinyl moiety in the bioactivity of various biologically active compounds. The piperazine analogs have been shown to Biological activity have a potent antimicrobial activity and they can also act as BACE-1 inhibitors. On the other hand, arylpiperazines linked to coumarin derivatives have been shown to have antiproliferative activity against leukemia, lung, colon, breast, and prostate tumors. Recently, it has been reported that coumarin- piperazine derivatives exhibit a Fneuroprotective effect by their antioxidant and anti-inflammatory activ- ities and they also show activity as acetylcholinesterase inhibitors and antifilarial activity. In this work we provide a summary of the latest advances in coumarin-related chemistry relevant for biological activity.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By

    This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By

    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
  • A Multitransmitter Approach to Dementia Treatment

    A Multitransmitter Approach to Dementia Treatment

    CNS Drug Reviews Vol. 8, No.2, pp. 143–158 © 2002 Neva Press, Branford, Connecticut Ensaculin (KA-672 × HCl): A Multitransmitter Approach to Dementia Treatment Robert Hoerr1 and Michael Noeldner2 1Clinical Research Department and 2Department of Pharmacology, Dr. Willmar Schwabe GmbH & Co., Karlsruhe, Germany Key Words: Ensaculin—Benzopyranone—Dementia—Neurotransmitters—Me- mory—Neuroprotection—5-HT1A—5HT7 —NMDA antagonists. ABSTRACT Ensaculin, a novel benzopyranone substituted with a piperazine moiety, showed memory-enhancing effects in paradigms of passive and conditioned avoidance in both normal and artificially amnesic rodents. It exhibited neuroprotective activities in an NMDA toxicity model and neurotrophic effects in primary cultured rat brain cells. The compound could be characterized as a weak NMDA receptor–operated channel blocker. In receptor-binding studies, ensaculin was found to have high affinities to serotonergic 5-HT1A and 5-HT7 receptors, adrenergic á1, and dopaminergic D2 and D3 receptors. Due to its unique pharmacodynamic profile, ensaculin may have potential as an antidementia agent acting on various transmitter systems. INTRODUCTION Alzheimer’s disease (AD) is a neurodegenerative disorder that predominantly affects aged people. It is the most frequent cause of dementia, thus gaining increasing importance as the population continues to age. Even though extensive research has been directed to- wards the understanding of this devastating illness, the formal and causal interrelation- ships of its pathogenetic determinants are still an enigma. The most distinctive morphological features of AD are amyloid deposition resulting in neuritic plaques, the formation of neurofibrillary tangles consisting of hyperphosphory- Address correspondence and reprint requests to: Dr. Robert Hoerr, Clinical Research Department, Dr. Willmar Schwabe GmbH & Co., Willmar-Schwabe-Strasse 4, 76227 Karlsruhe, Germany.
  • Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)

    Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)

    Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper Written by Warren Kaplan Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS) By Warren Kaplan, Ph.D., JD, MPH 15 February 2013 Update on 2004 Background Paper, BP 6.7 HIV/AIDS Table of Contents What is new since 2004? ..................................................................................................................................... 4 1. Introduction ................................................................................................................................................. 7 2. What are the Epidemiological Trends for Europe and the World? ................................................... 7 2.1 Western and Central Europe ............................................................................................................. 7 2.2 Eastern Europe .................................................................................................................................... 9 2.2 The World (including Europe) ........................................................................................................ 11 3. What is the Control Strategy? Is There an Effective Package of Control Methods Assembled into a “Control Strategy” for Most Epidemiological Settings?................................................................. 13 3.1 Is there a pharmaceutical ‘gap’? ....................................................................................................
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
  • Molecular Docking Studies of Coumarin Hybrids As Potential Acetylcholinesterase, Butyrylcholinesterase, Monoamine Oxidase A/B An

    Molecular Docking Studies of Coumarin Hybrids As Potential Acetylcholinesterase, Butyrylcholinesterase, Monoamine Oxidase A/B An

    Yusufzai et al. Chemistry Central Journal (2018) 12:128 https://doi.org/10.1186/s13065-018-0497-z Chemistry Central Journal REVIEW Open Access Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β‑amyloid inhibitors for Alzheimer’s disease Samina Khan Yusufzai1, Mohammad Shaheen Khan2*, Othman Sulaiman1, Hasnah Osman3 and Dalily Nabilah Lamjin2 Abstract Coumarins are the phytochemicals, which belong to the family of benzopyrone, that display interesting pharmaco- logical properties. Several natural, synthetic and semisynthetic coumarin derivatives have been discovered in decades for their applicability as lead structures as drugs. Coumarin based conjugates have been described as potential AChE, BuChE, MAO and β-amyloid inhibitors. Therefore, the objective of this review is to focus on the construction of these pharmacologically important coumarin analogues with anti-Alzheimer’s activities, highlight their docking studies and structure–activity relationships based on their substitution pattern with respect to the selected positions on the chromen ring by emphasising on the research reports conducted in between year 1968 to 2017. Keywords: Coumarin, Neurodegenerative disorder, Alzheimer’s disease, Acetylcholinesterase, Butyrylcholinesterase, Monoamine oxidase Introduction production and clearance of Aβ peptide and thus Aβ Alzheimer’s disease (AD) is the most common form forms highly insoluble and proteolysis resistant fbrils of neurodegenerative disorder and the most prevalent known as senile plaques (Fig. 1) [1]. Tese plaques will cause of dementia commonly afecting the elderly. It is a interrupt the neuron transmission at synapses and cause progressive disorder of the brain that is associated with information transfer to fail leading to the neuronal cell the loss of presynaptic markers of the cholinergic sys- death.
  • Pdf Standard Procedure for Data Transfer

    Pdf Standard Procedure for Data Transfer

    STANDARD PROCEDURE FOR DATA TRANSFER Version 2.5 / June 2017 Contact: [email protected] www.iedea-sa.org / www.iedea-hiv.org IeDEA Southern Africa Standard Procedures for Data Transfer Contents 1 Introduction ........................................................................................................... 1 1.1 General remarks ....................................................................................................... 1 1.2 Inclusion criteria for patients ...................................................................................... 1 1.3 Dates ...................................................................................................................... 2 1.4 Definitions ............................................................................................................... 3 1.5 Standard codes ......................................................................................................... 3 1.6 Data tables .............................................................................................................. 3 2 Variables to be included in core tables ....................................................................... 6 2.1 Socio-demographic characteristics and outcomes (PAT table) ......................................... 6 2.2 Laboratory data (LAB table) .......................................................................................13 2.3 Antiretroviral drug variables (ART table) .....................................................................16 2.4
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.